Sorrento Announces Publication of Data in Cell Press Journal Med Describing Discovery and Preclinical Efficacy of a Broadly-Acting SARS-CoV-2 Neutralizing Antibody Administered IV (STI-9167) or IN (STI-9199)

October 15, 2022

https://www.globenewswire.com/news-release/2022/10/14/2534914/0/en/Sorrento-Announces-Publication-of-Data-in-Cell-Press-Journal-Med-Describing-Discovery-and-Preclinical-Efficacy-of-a-Broadly-Acting-SARS-CoV-2-Neutralizing-Antibody-Administered-IV-.html

SAN DIEGO, Oct. 14, 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq:SRNE, “Sorrento”) today announced publication in the Cell Press journal Med of data detailing work relating to the discovery and preclinical profiling of STI-9167 neutralizing antibody activity against a broad collection of SARS-CoV-2 variants, including select Omicron subvariants. Protection from Omicron-related disease in vivo in a preclinical challenge model was observed following administration of STI-9167 by the intravenous (IV) route or following administration by the intranasal (IN) route using an intranasal formulation of STI-9167 antibody, termed STI-9199.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.